The effect of TOR on the terminal maturation of DC
| Treatment . | CD1a . | CD83 . | CD80 . | CD86 . | HLA-DR . |
|---|---|---|---|---|---|
| Control | 8.7 ± 5.8 | 1.7 ± 0.9 | 11 ± 7.6 | 11 ± 10 | 95 ± 92 |
| TOR | 6.5 ± 2.6 | 1.5 ± 0.4 | 7.9 ± 4.1 | 7.8 ± 6.4 | 51 ± 48 |
| LPS | 14 ± 5.1 | 13 ± 5.9 | 38 ± 26 | 89 ± 72 | 430 ± 350 |
| TOR + LPS | 10 ± 3.73-150 | 8.7 ± 4.03-150 | 30 ± 20 | 76 ± 61 | 290 ± 2903-150 |
| TNF-α | 9.4 ± 4.4 | 5.2 ± 3.4 | 15 ± 8.8 | 25 ± 19 | 210 ± 180 |
| TOR + TNF-α | 6.6 ± 3.63-150 | 4.6 ± 3.2 | 12 ± 11 | 34 ± 40 | 130 ± 1503-150 |
| Treatment . | CD1a . | CD83 . | CD80 . | CD86 . | HLA-DR . |
|---|---|---|---|---|---|
| Control | 8.7 ± 5.8 | 1.7 ± 0.9 | 11 ± 7.6 | 11 ± 10 | 95 ± 92 |
| TOR | 6.5 ± 2.6 | 1.5 ± 0.4 | 7.9 ± 4.1 | 7.8 ± 6.4 | 51 ± 48 |
| LPS | 14 ± 5.1 | 13 ± 5.9 | 38 ± 26 | 89 ± 72 | 430 ± 350 |
| TOR + LPS | 10 ± 3.73-150 | 8.7 ± 4.03-150 | 30 ± 20 | 76 ± 61 | 290 ± 2903-150 |
| TNF-α | 9.4 ± 4.4 | 5.2 ± 3.4 | 15 ± 8.8 | 25 ± 19 | 210 ± 180 |
| TOR + TNF-α | 6.6 ± 3.63-150 | 4.6 ± 3.2 | 12 ± 11 | 34 ± 40 | 130 ± 1503-150 |
First, adherent PBMC or sorted CD14+ cells were cultured with IL-4 + GM-CSF for 7 days. On days 3 and 5, 200 μL medium was replaced with new medium including IL-4 (500 U/mL) and GM-CSF (50 ng/mL). After 7 days of culture, LPS (1 μg/mL), TNF-α (10 ng/mL) and/or TOR (5 μmol/L) was added. After an additional 24 hours, the cells were stained for various cell surface markers and analyzed with flow cytometry. The data represent MFIRs (see “Materials and methods”) of 5 individual experiments (mean ± SD).
P < .05 comparing TOR versus control, LPS versus TOR + LPS, and TNF-α versus TOR + TNF-α.